Skip to content

Study · Observational study · n = 220 · 2024

3 results

Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.

Nersessian RSF, da Silva LM, Carvalho MAS, Silveira SQ, Abib ACV, Bellicieri FN, Lima HO, Ho AM, Anjos GS, Mizubuti GB

Anaesthesia22 Oct 2024Cited by 45 (Europe PMC)

PMID39435967 (opens in a new tab)DOI10.1111/anae.16454 (opens in a new tab)PepBankPUB-39435967
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In surgical patients, increased residual gastric content was found in 40% of those given semaglutide within 10 days and 3% of those not given it.

    In plain wordsIn surgical patients, more people on semaglutide within 10 days of surgery had food or fluid in the stomach than people not on it.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncreased residual gastric content on ultrasound
    Study

    n = 220

    Comparator
    Patients not exposed to semaglutide
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Increased residual gastric content
    40%
    semaglutide group
    Increased residual gastric content
    3%
    non-semaglutide group

    Source sentences

    Summary
    Increased residual gastric content was found in 43/107 patients (40%) in the semaglutide group and 3/113 (3%) in the non-semaglutide group (p < 0.001).
    1 context sentence
    Summary · context
    In this prospective observational study, we recruited patients who received pre-operative once-weekly subcutaneous semaglutide within 10 days of the procedure (semaglutide group) and control patients who had not been exposed to semaglutide (non-semaglutide group).
  2. 02HumanObservational studySafety outcome

    In propensity-weighted analysis, semaglutide use was significantly associated with increased residual gastric content.

    In plain wordsIn surgical patients, semaglutide use was linked to more stomach content before surgery, even after adjusting for other factors.

    Peptide
    Semaglutide
    Outcome
    IncreaseAssociation of semaglutide use with increased residual gastric content
    Study

    n = 220

    Comparator
    Patients not exposed to semaglutide
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    OR
    36.97 ratio
    semaglutide use
    95% CI
    16.54 to 99.32 ratio
    semaglutide use

    Source sentences

    Summary
    In propensity-weighted analysis, semaglutide use (OR 36.97, 95%CI 16.54-99.32)
    1 context sentence
    Summary · context
    In this prospective observational study, we recruited patients who received pre-operative once-weekly subcutaneous semaglutide within 10 days of the procedure (semaglutide group) and control patients who had not been exposed to semaglutide (non-semaglutide group).
  3. 03HumanObservational studySafety outcome

    In surgical patients, there were no cases of pulmonary aspiration of gastric contents.

    In plain wordsIn this surgical study, no patient breathed stomach contents into the lungs.

    Peptide
    Semaglutide
    Outcome
    No significant changePulmonary aspiration of gastric contents
    Study

    n = 220

    Outcome group
    Adverse events · Respiratory
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were no cases of pulmonary aspiration of gastric contents.
    1 context sentence
    Summary · context
    In this prospective observational study, we recruited patients who received pre-operative once-weekly subcutaneous semaglutide within 10 days of the procedure (semaglutide group) and control patients who had not been exposed to semaglutide (non-semaglutide group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.